Loading
Life sciences · Interventional Study
ClinicalTrials.gov · September 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04404153). This is a study registration, not published results. Lead sponsor: Albert Einstein College of Medicine. Recruitment status: COMPLETED. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 100 participants (ACTUAL). Conditions: Alzheimer Disease, Dementia. Interventions: DEVICE: tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver active tDCS.; DEVICE: tDCS device model Soterix mini-CT (Soterix Medical Inc., New York, NY) programed to deliver sham tDCS.. Primary outcome measures: Global Cognitive Performance , Baseline, at 6 months (immediately after the 6-month intervention); Functional Neuroplasticity-Digit Symbol Substitution , Baseline, at 6 months (immediately after the 6-month intervention) and 9-months (3 months post-intervention).; Functional Neuroplasticity - Flanker Interference Task , Baseline, at 6 months (immediately after the 6-month intervention) and 9-months (3 months post-intervention).. Brief summary: The prevalence of Alzheimer's Disease (AD) is rising, but existing medications provide only modest control of cognitive decline and associated symptoms, and novel therapies are urgently needed. This randomized sham-controlled trial will determine if an innovative low-risk remotely-supervised transcranial Direct Current Stimulation (tDCS) applied over the area of the dorsolateral prefrontal cortex for 30 minutes at the intensity of 2 mA five times per week for 6 months at home can improve cognitive performance and symptoms and modulate neuroimaging markers of neuroplasticity in 100 patients with mild to moderate AD. If effective, this novel intervention can substantially enhance AD symptom management at home, improve quality of life of AD patients and their families, and reduce burden associated with this debilitating illness.